Latest:
Dr Koo on Challenges With PSMA PET in Prostate Cancer
Phillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Alessandro Di Federico, MD
Latest:
Dr Di Federico on an Analysis of TTF-1 Expression in Lung Adenocarcinoma
Alessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.
Evelyn Y.T. Wong, MD
Evelyn Y. Wong, MD, is a Consultant Medical Oncologist of Gastrointestinal Cancer at the National Cancer Centre Singapore.
Latest:
Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD
Dr Wong discusses the growing challenge of early-onset colorectal cancer and the insights from a recent cohort analysis conducted in Singapore.
Lowell B Anthony, MD, FACP
Latest:
AE Management of Cabozantinib
Panelists discuss how managing cabozantinib’s adverse effects requires proactive patient counseling about expected dose reductions, aggressive supportive care for manageable toxicities like hypertension and diarrhea, frequent early monitoring, and recognition that the median effective dose (40 mg) is lower than the starting dose (60 mg).
Douglas B. Flora, MD, LSSBB
Douglas B. Flora, MD, LSSBB, is the executive medical director of Oncology Services and the Robert and Dell Ann Sathe Endowed Chair in Oncology at St. Elizabeth Healthcare.
Latest:
Dr Flora on the Potential Role of AI in Clinical Trial Screening and Design for Oncology
Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.
John Kirkwood, DO
Latest:
RP1: An Emerging Intratumoral Therapy
Panelists discuss the promising systemic responses of RP1, an oncolytic virus therapy for melanoma, emphasizing its expanded applicability through visceral tumor injection and the need for further data to optimize dosing strategies and confirm durability compared with other treatments.
David C. Fisher, MD
Latest:
CTCL Today: Remaining Unmet Needs in CTCL
Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.